|
|
|
WHO prequalification of Artesunate + Amodiaquine
WHO Prequalification Programme has just added the ACT (Artemisinin-based Combination Therapy) Artesunate + Amodiaquine 50mg + 150mg tablets manufactured by the Chinese pharmaceutical manufacturer, Guilin Pharmaceutical Co., to its list of prequalified medicines.
Guilin is considered the originator of Artesunate tablets and the only Chinese manufacturer holding a WHO prequalification of Artesunate tablets, Amodiaquine tablets as well as the ACT, Artesunate + Amodiaquine.
The WHO Prequalification Programme was created by the World Health Organization in 2001.
|
/Amodiaquine.jpg)
|
The purpose of the programme is to increase access to priority pharmaceutical products that meet unified standards of acceptable quality, safety and efficacy, currently focusing on those used for HIV/AIDS, Malaria, Tuberculosis and for Reproductive Health.
Being added to WHO’s list of prequalified medicines, Guilin’s ACT product has been found acceptable for procurement by UN agencies as well as any agency or organization involved in bulk purchasing of medicines at country or international level.
|
|
|
/line_grey.jpg)
/arrow_news.gif){kind=icon}